Evidence map›Paper›PMID 36143237›Full record

ArticleJournal of personalized medicine2022

CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis.

Alejandra Reolid, Antonio Sahuquillo-Torralba, Ancor Sanz-García, Rafael Botella-Estrada, Ester Muñoz-Aceituno, Mar Llamas-Velasco, Jorge García-Martínez, Esteban Daudén, Francisco Abad-Santos, María C Ovejero-Benito

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Alejandra ReolidDepartment of Dermatology, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, 28006 Madrid, Spain.ORCID 0000-0002-1501-9287
Antonio Sahuquillo-TorralbaDepartment of Dermatology, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
Ancor Sanz-GarcíaData Analysis Unit, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de la Princesa, (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-5024-5108
Rafael Botella-EstradaDepartment of Dermatology, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
Ester Muñoz-AceitunoDepartment of Dermatology, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, 28006 Madrid, Spain.ORCID 0000-0003-4227-2728
Mar Llamas-VelascoDepartment of Dermatology, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, 28006 Madrid, Spain.ORCID 0000-0002-1187-1341
Jorge García-MartínezData Analysis Unit, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de la Princesa, (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0003-1566-8145
Esteban DaudénDepartment of Dermatology, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, 28006 Madrid, Spain.
Francisco Abad-SantosClinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-6519-8885
María C Ovejero-BenitoClinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0003-4082-5165
Hospital Universitario de La Princesa · ESInstituto de Investigación Sanitaria La Fe · ESInstituto de Salud Carlos III · ESUniversitat de València · ES

Funding

Instituto de Investigación Sanitaria La Fe NAInstituto de Salud Carlos III PI 2017/0348
6 · The paper itself

Abstract

backgroundPsoriasis can present different phenotypes and could affect diverse body areas. In contrast to the high effectiveness of biological drugs in the treatment of trunk and extremities plaque psoriasis, in palmoplantar phenotypes and in plaque scalp psoriasis, these same drugs usually have reduced efficacy. Anti-TNF drugs could induce the appearance of palmoplantar pustulosis (PPP) in patients with other inflammatory diseases. The objective of this study is to identify if there are DNA Copy Number Variations (CNVs) associated with these different clinical phenotypes, which could justify the differences found in clinical practice. Moreover, we intend to elucidate if anti-TNF-induced PPP has a similar genetic background to idiopathic PPP.

methodsSkin samples were collected from 39 patients with different patterns of psoriasis and six patients with anti-TNF-induced PPP. The CNVs were obtained from methylation array data (Illumina Infinium Human Methylation) using the conumee R package.

resultsNo significant CNVs were found between the different phenotypes and the locations of psoriasis compared. Nevertheless, we found two significant bins harboring five different genes associated with anti-TNF-induced PPP in patients with a different background other than psoriasis.

conclusionsOur results may help to predict which patients could develop anti-TNF-induced PPP.

Indexed as

adverse effect predictionbiological drugspharmacogenomicspsoriasis genetics methylation array

Identifiers

PMID36143237
PMCPMC9506507
OpenAlexW4295067613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.